Cancer BiologybioRxiv
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
O. A. Romero, A. Villarrubi, J. J. Alburquerque-Bejar…·M. Sanchez-Cespedes
This study identifies KDM6A/UTX and KDM6B/JMJD3 as therapeutic targets in SMARCA4-deficient cancers, showing that their inhibition reduces tumor viability in mouse models.